144 related articles for article (PubMed ID: 17536796)
1. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion.
McDonald IM; Black JW; Buck IM; Dunstone DJ; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Pether MJ; Roberts SP; Shaxted ME; Spencer J; Steel KI; Sykes DA; Walker MK; Watt GF; Wright L; Wright PT; Xun W
J Med Chem; 2007 Jun; 50(13):3101-12. PubMed ID: 17536796
[TBL] [Abstract][Full Text] [Related]
2. Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.
Buck IM; Black JW; Cooke T; Dunstone DJ; Gaffen JD; Griffin EP; Harper EA; Hull RA; Kalindjian SB; Lilley EJ; Linney ID; Low CM; McDonald IM; Pether MJ; Roberts SP; Shankley NP; Shaxted ME; Steel KI; Sykes DA; Tozer MJ; Watt GF; Walker MK; Wright L; Wright PT
J Med Chem; 2005 Nov; 48(22):6803-12. PubMed ID: 16250639
[TBL] [Abstract][Full Text] [Related]
3. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
[TBL] [Abstract][Full Text] [Related]
4. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Nishida A; Miyata K; Tsutsumi R; Yuki H; Akuzawa S; Kobayashi A; Kamato T; Ito H; Yamano M; Katuyama Y
J Pharmacol Exp Ther; 1994 May; 269(2):725-31. PubMed ID: 7910212
[TBL] [Abstract][Full Text] [Related]
6. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
[TBL] [Abstract][Full Text] [Related]
7. Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
Allison BD; Phuong VK; McAtee LC; Rosen M; Morton M; Prendergast C; Barrett T; Lagaud G; Freedman J; Li L; Wu X; Venkatesan H; Pippel M; Woods C; Rizzolio MC; Hack M; Hoey K; Deng X; King C; Shankley NP; Rabinowitz MH
J Med Chem; 2006 Oct; 49(21):6371-90. PubMed ID: 17034143
[TBL] [Abstract][Full Text] [Related]
8. Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template.
Spencer J; Gaffen J; Griffin E; Harper EA; Linney ID; McDonald IM; Roberts SP; Shaxted ME; Adatia T; Bashall A
Bioorg Med Chem; 2008 Mar; 16(6):2974-83. PubMed ID: 18289857
[TBL] [Abstract][Full Text] [Related]
9. Necessity of intracellular cyclic AMP in inducing gastric acid secretion via muscarinic M3 and cholecystokinin2 receptors on parietal cells in isolated mouse stomach.
Ochi Y; Horie S; Maruyama T; Watanabe K; Yano S
Life Sci; 2005 Sep; 77(16):2040-50. PubMed ID: 15919097
[TBL] [Abstract][Full Text] [Related]
10. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
Morton MF; Barrett TD; Freedman J; Li L; Rizzolio MC; Prendergast CE; Wu X; Moreno V; Pyati J; Figueroa K; Cagnon L; Lagaud G; Ver Donck L; Ghoos E; Allison B; Rabinowitz MH; Shankley NP
J Pharmacol Exp Ther; 2011 Jul; 338(1):328-36. PubMed ID: 21493750
[TBL] [Abstract][Full Text] [Related]
11. RP 73870, a gastrin/cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat.
Pendley CE; Fitzpatrick LR; Capolino AJ; Davis MA; Esterline NJ; Jakubowska A; Bertrand P; Guyon C; Dubroeucq MC; Martin GE
J Pharmacol Exp Ther; 1995 Jun; 273(3):1015-22. PubMed ID: 7791071
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists.
Bertrand P; Böhme GA; Durieux C; Guyon C; Capet M; Jeantaud B; Boudeau P; Ducos B; Pendley CE; Martin GE
Eur J Pharmacol; 1994 Sep; 262(3):233-45. PubMed ID: 7813588
[TBL] [Abstract][Full Text] [Related]
13. 5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors.
Muñoz-Ruiz P; García-López MT; Cenarruzabeitia E; Del Río J; Dufresne M; Foucaud M; Fourmy D; Herranz R
J Med Chem; 2004 Oct; 47(21):5318-29. PubMed ID: 15456276
[TBL] [Abstract][Full Text] [Related]
14. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP
J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
Hirst GC; Aquino C; Birkemo L; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Henke B; James MK; Johnson MF; Momtahen T; Queen KL; Sherrill RG; Szewczyk J; Willson TM; Sugg EE
J Med Chem; 1996 Dec; 39(26):5236-45. PubMed ID: 8978852
[TBL] [Abstract][Full Text] [Related]
16. Biological activity of analogues of YM022. Novel (3-amino substituted phenyl)urea derivatives of 1,4-benzodiazepin-2-one as gastrin/cholecystokinin-B receptor antagonists.
Satoh M; Okamoto Y; Koshio H; Ohta M; Nishida A; Akuzawa S; Miyata K; Mase T; Semple G
Chem Pharm Bull (Tokyo); 1996 Jul; 44(7):1412-4. PubMed ID: 8706146
[TBL] [Abstract][Full Text] [Related]
17. Validation of a conscious rat model for the discovery of novel agents that inhibit gastric acid secretion.
Campbell CA; Gaskin PJ; Darton J; Chiu P; Lee K; McLean PG
Eur J Pharmacol; 2008 Jul; 589(1-3):260-3. PubMed ID: 18571645
[TBL] [Abstract][Full Text] [Related]
18. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
Henke BR; Aquino CJ; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; Hirst GC; James MK; Johnson MF; Queen KL; Sherrill RG; Sugg EE; Suh EM; Szewczyk JW; Unwalla RJ; Yingling J; Willson TM
J Med Chem; 1997 Aug; 40(17):2706-25. PubMed ID: 9276016
[TBL] [Abstract][Full Text] [Related]
19. Discovery and characterization of novel, potent, non-peptide parathyroid hormone-1 receptor antagonists.
McDonald IM; Austin C; Buck IM; Dunstone DJ; Gaffen J; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Patel D; Pether MJ; Raynor M; Roberts SP; Shaxted ME; Spencer J; Steel KI; Sykes DA; Wright PT; Xun W
J Med Chem; 2007 Oct; 50(20):4789-92. PubMed ID: 17850061
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid CB1 and cholecystokinin CCK2 receptors modulate, in an opposing way, electrically evoked [3H]GABA efflux from rat cerebral cortex cell cultures: possible relevance for cortical GABA transmission and anxiety.
Antonelli T; Tomasini MC; Mazza R; Fuxe K; Gaetani S; Cuomo V; Tanganelli S; Ferraro L
J Pharmacol Exp Ther; 2009 May; 329(2):708-17. PubMed ID: 19197005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
